NCT02429843View on ClinicalTrials.gov

A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 2, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2019

Conditions
Lung Cancer
Interventions
DRUG

TRC105

Each patient will be dosed with 6, 8, or 10 mg/kg of TRC105 up to a maximum dose of 850 mg for women and 1,000 mg for men based upon overall body weight.

Trial Locations (1)

35233

UAB Comprehensive Cancer Center, Birmingham

All Listed Sponsors
collaborator

Tracon Pharmaceuticals Inc.

INDUSTRY

lead

University of Alabama at Birmingham

OTHER

NCT02429843 - A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer | Biotech Hunter | Biotech Hunter